[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641819":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":11,"responsibleParty":31,"collaborators":11,"id":34,"slug":11,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":37,"acronym":38,"eligibilityCriteria":39,"healthyVolunteers":35,"sex":40,"minAge":41,"maxAge":11,"enrollmentInfo":42,"targetDuration":11,"studyType":45,"phases":46,"briefSummary":48,"conditions":49,"keywords":56,"overallStatus":65,"whyStopped":11,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":11},{"fullName":5,"class":6},"Centre Hospitalier de la côte Basque","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Connected home blood pressure monitoring with daily IPA supervision","EXPERIMENTAL",null,[13],"Device: Connected home blood pressure monitoring with daily IPA supervision.",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DEVICE","Connected home blood pressure monitoring with daily IPA supervision.","Use of a validated connected blood pressure monitor with Bluetooth gateway; standardized patient training; daily monitoring of transmitted BP measurements; scheduled clinical visits and telephone follow-up by the IPA.",[9],[21],{"name":22,"affiliation":23,"role":24},"Vanessa BEAU","Centre Hospitalier Côte Basque","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":11,"email":30},"Séverine LABARRERE","CONTACT","+33559443828","slabarrere@ch-cotebasque.fr",{"type":24,"investigatorFullName":32,"investigatorTitle":33,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"Mme BEAU Vanessa","Study nurse","100641819",false,"NCT07592481","Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK Inhibitors","HEMO-CONNECT","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosis of lymphoid malignancy: chronic lymphocytic leukemia, follicular lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma, Waldenström macroglobulinemia, or mantle cell lymphoma\n* Initiation of oral BTK inhibitor therapy (ibrutinib, acalabrutinib, or zanubrutinib), in treatment-naive or relapsed patients\n* Affiliation with a social security system\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Known cognitive impairment\n* No internet access\n* Individuals under guardianship, curatorship, or legal protection","ALL","18 Years",{"count":43,"type":44},40,"ESTIMATED","INTERVENTIONAL",[47],"NA","This pilot prospective study aims to evaluate adherence to home blood pressure monitoring using connected blood pressure (BP) devices in patients with malignant B-cell hemopathies initiating covalent Bruton tyrosine kinase inhibitors (cBTKi). The objective is to determine whether digital BP monitoring improves early detection and management of BTKi-induced hypertension over 6 months.",[50,51,52,53,54,55],"Chronic Lymphocytic Leukemia (CLL)","Follicular Lymphoma ( FL)","Waldenstrom Macroglobulinaemia","Lymphoplasmacytic Lymphoma","Marginal Zone B Cell Lymphoma","Mantle Cell Lymphoma",[57,58,59,60,61,62,63,64],"BTK inhibitor","Hypertension","Telemonitoring","Connected device","Blood pressure","Lymphoid malignancies","Advanced practice nursing","Cardio-oncology","NOT_YET_RECRUITING","2026-06-18",{"date":68,"type":69},"2026-06-22","ACTUAL",{"date":71,"type":44},"2026-07-01",{"date":73,"type":44},"2027-12-31",{"name":5,"class":6}]